Lesopitron

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lesopitron
Lesopitron.png
Clinical data
Routes of
administration		 Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C15H21ClN6
Molar mass 320.82 g/mol
3D model (Jmol)

Lesopitron (E-4424) is a selective full agonist of the 5-HT1A receptor which is structurally related to the azapirones.[1] In 2001 it was under development by Esteve as an anxiolytic for the treatment of generalized anxiety disorder (GAD).[2][3] It made it to phase II clinical trials but was apparently discontinued as no new information on lesopitron has surfaced since.[2][3]

See also[edit]

References[edit]

  1. ^ Haj-Dahmane S, Jolas T, Laporte AM, et al. (April 1994). "Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat". European Journal of Pharmacology. 255 (1-3): 185–96. doi:10.1016/0014-2999(94)90097-3. PMID 8026543. 
  2. ^ a b Micheli F (February 2001). "Lesopitron (Esteve)". IDrugs : the Investigational Drugs Journal. 4 (2): 218–24. PMID 16032484. 
  3. ^ a b Fresquet A, Sust M, Lloret A, et al. (February 2000). "Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder". The Annals of Pharmacotherapy. 34 (2): 147–53. doi:10.1345/aph.19041. PMID 10676820. 


Retrieved from "https://en.wikipedia.org/w/index.php?title=Lesopitron&oldid=678945802"